ArticleScientific reports2013
In vitro hematological and in vivo vasoactivity assessment of dextran functionalized graphene.
Article in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 64 citations in OpenAlex.
- Graphene-based materials: an innovative approach for neural regeneration and spinal cord injury repair.RSC advances · 2025Review
- Efficient skin interactions of graphene derivatives: challenge, opportunity or both?Nanoscale advances · 2023Article
- Synthesis and Functionalization of Graphene Materials for Biomedical Applications: Recent Advances, Challenges, and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Application of non-metal nanoparticles, as a novel approach, for improving the stability of blood products: 2011-2021.Progress in biomaterials · 2022Review
- Graphene Family Nanomaterials in Ocular Applications: Physicochemical Properties and Toxicity.Chemical research in toxicology · 2021Review
- Microparticles from aged packed red blood cell units stimulate pulmonary microthrombus formation via P-selectin.Thrombosis research · 2020Article
- Recent advances in graphene-based nanomaterials: properties, toxicity and applications in chemistry, biology and medicine.Mikrochimica acta · 2019Review
- New generation of drug delivery systems based on ginsenoside Rh2-, Lysine- and Arginine-treated highly porous graphene for improving anticancer activity.Scientific reports · 2018Article
- Metabolomic insights of macrophage responses to graphene nanoplatelets: Role of scavenger receptor CD36.PloS one · 2018Article
- Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities.Graphene technology · 2016Article
- Toxicology of graphene-based nanomaterials.Advanced drug delivery reviews · 2016Review
- Towards An Advanced Graphene-Based Magnetic Resonance Imaging Contrast Agent: Sub-acute Toxicity and Efficacy Studies in Small Animals.Scientific reports · 2015Article
- Article
- Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme.Nanomedicine : nanotechnology, biology, and medicine · 2015Article
- Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein.Acta biomaterialia · 2014Article
- Injectable graphene oxide/hydrogel-based angiogenic gene delivery system for vasculogenesis and cardiac repair.ACS nano · 2014Article
- Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations.Biomaterials · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intravenous, intramuscular or intraperitoneal administration of water solubilized graphene nanoparticles for biomedical applications will result in their interaction with the hematological components and vasculature. Herein, we have investigated the effects of dextran functionalized graphene nanoplatelets (GNP-Dex) on histamine release, platelet activation, immune activation, blood cell hemolysis in vitro, and vasoactivity in vivo. The results indicate that GNP-Dex formulations prevented histamine release from activated RBL-2H3 rat mast cells, and at concentrations ≥ 7 mg/ml, showed a 12-20% increase in levels of complement proteins. Cytokine (TNF-Alpha and IL-10) levels remained within normal range. GNP-Dex formulations did not cause platelet activation or blood cell hemolysis. Using the hamster cheek pouch in vivo model, the initial vasoactivity of GNP-Dex at concentrations (1-50 mg/ml) equivalent to the first pass of a bolus injection was a brief concentration-dependent dilation in arcade and terminal arterioles. However, they did not induce a pro-inflammatory endothelial dysfunction effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.